Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, a public interest team of attorneys and scientists who ensure that patents do not obstruct access to affordable medicines for patients in the United States and around the world, discusses transparency in drug pricing.
Transcript:
Drug makers often argue that developing a drug is so costly that high prices are warranted to recoup their costs and reward innovation. What do you think about that argument?
I think that’s a fair argument, and we know that there are a lot of costs that go into drug development and research. What those exact costs are we don’t exactly know, it’s a bit of a black box, and I think some transparency around that would be helpful so that these debates and these discussions can be more informed. But we don’t believe that all the various patents that are being filed warrant or explain all the costs and the sort of profits that are being made as a result of these strategies that companies are using in order to prevent competition.
I think those are separate issues, and they need to be unpackaged better to have a better policy to help both the payers and the public in order to get fairer pricing; but also to actually better improve what kind of [research and development, R&D] is done, what kind of innovation comes out of the system because at the moment I feel the patent system is an incentive mechanism which is not functioning at its highest possible way.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.